This article was released as Pharm Edaily Premium Content on November 14, 2025, at 8:34 AM.


[Shin-Min Joon, Edaily Reporter] On the 13th Curiosis, Cellumed and ABLBio stood out in the South Korean biotech and pharmaceutical stock market.
Curiosis a lab automation company saw its share price quadr 릴게임추천 uple from the IPO price on its KOSDAQ debut. Investor enthusiasm was driven by expectations for growth in the lab automation market, which uses robotics and computer technologies to streamline drug de 야마토게임 velopment and cell therapy testing and analysis.
Cellumed attracted strong buying interest amid expectations of improved earnings following the launch of a new high performance skin graft p 알라딘게임 roduct based on acellular dermal matrix (ADM). Meanwhile, ABLBio’s stock soared for a second consecutive day on the back of a major technology transfer deal with global pharma giant Eli Lilly.
야마토게임하기


Curiosis stock trend on Nov 13.(Image=MP Doctor)



Curiosis shares surge four fold on first trading day

10원야마토게임 On the 13th in the domestic pharmaceutical and biotech stock market, the share movements of Curiosis, Cellumed and ABL Bio stood out.
Laboratory automation company Curiosis saw its share price jump 300% from the previous day to 88,000won on its debut on the KOSDAQ market according to KG Zeroin MP Doctor (formerly MarketPoint). The company’s public offering price stood at 22,000won.
In the preceding demand forecast a total of 2,210 institutions participated, recording a competition ratio of 1,031.4 to 1. Some 99.91%(2,208 cases) of the participating institutional investors offered prices at or above the upper end of the public offering band (18,000won~22,000won). Notably the ratio of institutions committing to a mandatory lock up reached 67.6% the highest on record since the IPO policy for KOSDAQ companies was strengthened.
Founded in 2015 Curiosis has completed its CurioSystem platform by integrating ten years of core source technologies for lab automation. Its flagship products include the Celloger series and the automated colony picker CPX, a key instrument in synthetic biology.
The Celloger series is a live cell imaging system designed to observe and record samples in real time within an incubator (cell culture chamber) at 100% humidity minimizing heat emission. Previously, plates under culture had to be removed periodically for manual observation, a labour intensive process carrying risks of contamination temperature fluctuation and mechanical disturbance of cells.
The Celloger system fixes the sample plate and only moves the optical system (camera/lens) thereby suppressing vibration. Designed for automation it supports long term monitoring and data accumulation and the Celloger series has been sold in 29 countries so far.
The CPX automates the earlier manual process of selecting and transferring microbial colonies via precise motor control improving speed accuracy and reducing risk of contamination. The CPXα has even been used in standardisation work at the Korean Institute of Bioscience & Biotechnology’s Bio foundry.
The lab automation market is also growing rapidly because lab automation reduces repetitive tasks, increases personnel efficiency and enhances data accuracy and reliability. It also enables 24hour laboratory operation by reducing human error. According to the market research firm Kings Research, the global laboratory automation market which stood at US$72.3billion (about 106trillion won) last year is expected to expand to US$117.9billion (about 173trillion won) by 2032. Curiosis recorded last year sales of 4.7billion won and expects to turn a profit next year. The company’s goal is sales of 47billion won by 2028.
A Curiosis representative commented “We believe that Curiosis’ differentiated technological edge and market expectations for lab automation had a positive influence on our share price.”
Cellumed sees growth expectations for ADM based skin grafts
Cellumed’s share price rose 30% to 858won that day. The company is seeing growing expectations for its high functionality skin graft products based on acellular dermal matrix (ADM).
Cellumed offers a lineup of Celluderm series products Celluderm HD Implant, Celluderm Fill and Celluderm Ultra. These grafts are evaluated as having better safety and functionality compared with existing products in skin reconstruction and regeneration procedures. The HD Implant enables high precision custom design; the Ultra product allows control over absorption rate and tissue regeneration speed, improving surgical efficiency. Notably the newly launched Celluderm?Fill is an injectable formulation in which ADM is finely powdered and mixed with purified water optimised for reconstructive surgeries such as breast reconstruction.
In the recent domestic and international plastic surgery market, grafts based on allogeneic dermis are gaining attention thanks to their improved biocompatibility and safety compared with synthetic materials.
Cellumed has aligned with this trend and differentiated its technology. From 9 to 11 November, the company participated in the PRS KOREA 2025 conference held at the Grand InterContinental Seoul Parnas in Samseong dong Seoul and demonstrated its high performance skin graft technology.
A Cellumed spokesperson noted “During the event medical professionals continuously visited the Cellumed booth” adding that “through meetings we emphasised that the applications of allogeneic dermis are expanding beyond breast reconstruction into urology cosmetic dermatology and burn treatment.”
The spokesperson added “Going forward we plan to actively participate in major domestic and international academic conferences to further communicate the Celluderm series’ technology and clinical competitiveness. Based on differentiated quality, Cellumed will deploy an aggressive sales and marketing strategy to secure a competitive edge in the skin graft market.”
ABLBio maintains momentum from EliLilly tech transfer deal
The share price of ABLBio hit 163,500won that day, up 29.04% from the previous day marking a second consecutive day of sharp gains. During the trading session the price rose to as high as 164,700won reaching the maximum daily gain limit (29.99%) and hitting a new 52week high.
ABLBio recently signed a major technology transfer and joint R&D agreement for its Grabody platform with global pharma giant Eli Lilly and Company. Under the contract ABLBio is slated to receive an upfront payment of US$40million (about 58.5billion won) and is eligible to receive up to US$2.562billion (about 3.7487trillion won) in development regulatory and commercial milestone payments plus royalties based on product net sales.ABLBio representative said “This technology transfer agreement reaffirmed the commercialisation potential of our Grabody platform and the ongoing expansion of modalities to which it can be applied is highly encouraging.”
The spokesperson added “The Grabody platform currently holds a very strong standing and we plan to leverage this momentum by extending its indications into obesity and muscle disease areas where unmet medical needs are large.”
신민준 (adonis@edaily.co.kr) 기자 admin@reelnara.info